FDA Patient-Focused Drug Development (PFDD) Guidance

Date:
February 1, 2023
Time (PT):
9:38 AM

This is part one of a two part ISPOR webinar series. The FDA is developing Patient-Focused Drug Development (PFDD) guidance to inform the inclusion of patient experience when developing new medical therapies and products. This is a four-part guidance series, with two final guidances released, a third draft guidance released and a fourth guidance under development. The PFDD guidance is anticipated to be influential in the field of health economics and outcomes research. In this webinar series, we will hear from patients and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development.

Open to all ISPOR Members and Non-members. Learn more.

Related Content

Related Content